comprehensive -WSS

comprehensive

author：fashion 2025-09-27 13:11:02 - browse：72

Portrait of Stacy Sanders -- health policy coverage from STAT — Stacy Sanders, the first-ever chief competition officer for HHS. Courtesy Department of Health and Human Services

The Department of Health and Human Services will name Stacy Sanders as its new chief competition officer, the agency announced Monday. The new position was recently created as part of an administration crackdown on corporate greed in health care.

“We know that increased competition in the marketplace is a good deal for the American people,” Sanders said in a statement. “I look forward to supporting the Biden-Harris Administration’s efforts to increase competition in health care and lower costs, helping build on steps the Administration has already taken as well as identify opportunities to further spur innovation.”

As chief competition officer, Sanders will look for ways the health department can promote competition in health care markets. She will also work with the Federal Trade Commission and the Department of Justice to develop new policy initiatives to address consolidation, and coordinate data-sharing and reciprocal training programs with the other two agencies. The FTC and DOJ are also getting new health care counsel positions to lead these efforts, the administration announced in December.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： State Dept. review finds Biden bears some blame for Afghanistan failures
Next article： Roche drug slashes death risk in early

WSS

Eli Lilly expects to double planned employment in Boston center

STAT Summit: The economic case for universal basic health care

STAT Summit: GSK CEO on pharma giant's new direction

2023 STAT Wunderkinds: get to know the winners

Beam Therapeutics to lay off 20% of its staff, re

How climate

Wikipedia

comprehensive

Wikipedia

Wildfire smoke exposes gaps in outdoor worker protections

CEOs share strategies for surviving biotech slump

FDA approval of Sarepta Duchenne genetic therapy gives me hope

Readout Newsletter: AstraZeneca's CEO, Roivant's $5 billion deal

Continuity nursing helped my family in our darkest PICU moments

CEOs share strategies for surviving biotech slump

Wildfire smoke exposes gaps in outdoor worker protections

Questions loom on AstraZeneca cancer drug as safety concerns ebb

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

The problems with dementia villages

focus

Will Ozempic

STAT Readout Newsletter: Biotech news today

Impact of Dobbs ruling felt at reproductive medicine meeting

Health tech investors get more selective as pandemic boom fades

The EU Joint Clinical Assessment needs to live up to its promise

Roche drug slashes death risk in early

leisure time

focus

knowledge

Wikipedia